AU2013279456A1 - Stabilized gp120 - Google Patents

Stabilized gp120 Download PDF

Info

Publication number
AU2013279456A1
AU2013279456A1 AU2013279456A AU2013279456A AU2013279456A1 AU 2013279456 A1 AU2013279456 A1 AU 2013279456A1 AU 2013279456 A AU2013279456 A AU 2013279456A AU 2013279456 A AU2013279456 A AU 2013279456A AU 2013279456 A1 AU2013279456 A1 AU 2013279456A1
Authority
AU
Australia
Prior art keywords
polypeptide
hiv
isolated polypeptide
stabilized
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013279456A
Other languages
English (en)
Inventor
Andrea Carfi
Antu DEY
Aemro KASSA
Indresh Srivastava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of AU2013279456A1 publication Critical patent/AU2013279456A1/en
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA reassignment GLAXOSMITHKLINE BIOLOGICALS SA Request for Assignment Assignors: NOVARTIS AG
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013279456A 2012-06-18 2013-06-17 Stabilized gp120 Abandoned AU2013279456A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261661050P 2012-06-18 2012-06-18
US61/661,050 2012-06-18
PCT/EP2013/062553 WO2013189901A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Publications (1)

Publication Number Publication Date
AU2013279456A1 true AU2013279456A1 (en) 2014-12-18

Family

ID=48628698

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013279456A Abandoned AU2013279456A1 (en) 2012-06-18 2013-06-17 Stabilized gp120

Country Status (14)

Country Link
US (1) US20150183835A1 (https=)
EP (1) EP2861249A1 (https=)
JP (1) JP2015521592A (https=)
KR (1) KR20150023735A (https=)
CN (1) CN104619338A (https=)
AU (1) AU2013279456A1 (https=)
CA (1) CA2876762A1 (https=)
IL (1) IL235898A0 (https=)
IN (1) IN2014KN02740A (https=)
MX (1) MX2014014682A (https=)
RU (1) RU2015101081A (https=)
SG (1) SG11201407995RA (https=)
WO (1) WO2013189901A1 (https=)
ZA (1) ZA201408840B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016037154A1 (en) * 2014-09-04 2016-03-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant hiv-1 envelope proteins and their use
RU2745373C2 (ru) * 2014-09-23 2021-03-24 БЁРИНГЕР ИНГЕЛЬХАЙМ ЭНИМАЛ ХЕЛТ ЮЭсЭй ИНК. Рекомбинантные вакцины от fmdv и их применение
EP3069730A3 (en) * 2015-03-20 2017-03-15 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10808011B2 (en) 2016-03-09 2020-10-20 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recombinant HIV-1 envelope proteins and their use
EP4613776A3 (en) 2016-10-21 2025-11-26 Altor BioScience Corporation Multimeric il-15-based molecules
WO2019079337A1 (en) 2017-10-16 2019-04-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RECOMBINANT HIV-1 ENVELOPE PROTEINS AND THEIR USE
CN109851664A (zh) * 2017-11-30 2019-06-07 清华大学 一种基于抗体反向表位设计的蛋白质及其在制备抗艾滋病病毒疫苗中的应用
MX2020013621A (es) 2018-06-19 2021-03-25 Nantcell Inc Composiciones y metodos de tratamiento de vih.
WO2021249013A1 (en) * 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Vaccine compositions, methods, and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786488B1 (fr) * 1998-11-27 2003-04-25 Orstom Mutants de la gp120 et leurs applications biologiques
HK1046911A1 (zh) * 1999-06-25 2003-01-30 Progenics Pharmaceuticals, Inc. 经稳定的病毒外膜蛋白质及其使用
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質
CA2774636C (en) * 2009-09-25 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use

Also Published As

Publication number Publication date
SG11201407995RA (en) 2015-01-29
IL235898A0 (en) 2015-01-29
JP2015521592A (ja) 2015-07-30
IN2014KN02740A (https=) 2015-05-08
ZA201408840B (en) 2016-08-31
EP2861249A1 (en) 2015-04-22
WO2013189901A1 (en) 2013-12-27
KR20150023735A (ko) 2015-03-05
MX2014014682A (es) 2015-03-04
CN104619338A (zh) 2015-05-13
RU2015101081A (ru) 2016-08-10
US20150183835A1 (en) 2015-07-02
CA2876762A1 (en) 2013-12-27

Similar Documents

Publication Publication Date Title
US20150183835A1 (en) Stabilized gp120
AU2017225144B2 (en) N-Terminal Deleted GP120 Immunogens
US10421789B2 (en) Engineered outer domain (EOD) of HIV GP120 and mutants thereof
EP3335728B1 (en) Biochemically stabilized hiv-1 env trimer vaccine
AU2021221582B2 (en) Compositions and methods related to HIV-1 immunogens
US20230338507A1 (en) Hiv-1 env fusion peptide immunogens and their use
WO2016037154A1 (en) Recombinant hiv-1 envelope proteins and their use
US20180194809A1 (en) Engineered outer domain (eod) of hiv gp120, mutants and use thereof
US9775895B2 (en) HIV therapeutics and methods of making and using same
US11872277B2 (en) Compositions and methods related to ebolavirus vaccines
WO2024036217A2 (en) Immunization strategies to more naturally guide the maturation of antibodies against human immunodeficiency virus (hiv) in hiv-infected subjects
Peterhoff et al. Lisa Rogers 3, 4, Georgios Pollakis 6, 7, Paul Tonks 2, Michael Hoelscher 3, 4, Song Ding 8, Rogier W. Sanders 9, 10, Christof Geldmacher 3, 4, Quentin Sattentau 11, Winfried Weissenhorn 5, Jonathan L. Heeney 2
WO2017007646A1 (en) Hiv-1 clade c envelope glycoproteins
EA050067B1 (ru) ПОЛИНУКЛЕОТИД, КОДИРУЮЩИЙ МОНОМЕР МОДИФИЦИРОВАННОГО ТРИМЕРНОГО БЕЛКА gp140 ОБОЛОЧКИ ВИЧ-1, СОДЕРЖАЩИЕ ЕГО ВЕКТОР И КЛЕТКА И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРЕДОТВРАЩЕНИЯ ИНФЕКЦИИ ВИЧ-1
EA041182B1 (ru) Композиции и способы, связанные с иммуногенами вич-1

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GLAXOSMITHKLINE BIOLOGICALS SA

Free format text: FORMER APPLICANT(S): NOVARTIS AG

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted